{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,11]],"date-time":"2026-04-11T15:34:11Z","timestamp":1775921651427,"version":"3.50.1"},"reference-count":71,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2011,9,9]],"date-time":"2011-09-09T00:00:00Z","timestamp":1315526400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0024505","type":"journal-article","created":{"date-parts":[[2011,9,10]],"date-time":"2011-09-10T01:44:14Z","timestamp":1315619054000},"page":"e24505","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Pre-Clinical Efficacy and Safety of Experimental Vaccines Based on Non-Replicating Vaccinia Vectors against Yellow Fever"],"prefix":"10.1371","volume":"6","author":[{"given":"Birgit","family":"Sch\u00e4fer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Georg W.","family":"Holzer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra","family":"Joachimsthaler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sogue","family":"Coulibaly","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Schwendinger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brian A.","family":"Crowe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Thomas R.","family":"Kreil","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P. Noel","family":"Barrett","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Falko G.","family":"Falkner","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2011,9,9]]},"reference":[{"key":"ref1","article-title":"Yellow fever.","year":"2009"},{"key":"ref2","first-page":"1101","article-title":"Flaviviridae: The viruses and their replication.","author":"BD Lindenbach","year":"2007"},{"key":"ref3","first-page":"1095","article-title":"Yellow Fever.","author":"TP Monath","year":"2004"},{"key":"ref4","first-page":"1153","article-title":"Flaviviruses.","author":"DJ Gubler","year":"2007"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S1473-3099(01)00016-0","article-title":"Yellow fever: an update.","volume":"1","author":"TP Monath","year":"2001","journal-title":"Lancet Infect Dis"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1016\/S0065-3527(03)60009-6","article-title":"Pathogenesis and pathophysiology of yellow fever.","volume":"60","author":"TP Monath","year":"2003","journal-title":"Adv Virus Res"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1002\/rmv.311","article-title":"The transmission of yellow fever to Macacus rhesus. 1928.","volume":"11","author":"A Stokes","year":"2001","journal-title":"Rev Med Virol"},{"key":"ref8","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1084\/jem.65.6.787","article-title":"The use of yellow fever virus modified by in vitro cultivation for human immunization.","volume":"65","author":"M Theiler","year":"1937","journal-title":"J Exp Med"},{"key":"ref9","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1006\/biol.1997.0056","article-title":"Yellow fever vaccines.","volume":"25","author":"AD Barrett","year":"1997","journal-title":"Biologicals"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"2222","DOI":"10.1056\/NEJMp0707161","article-title":"Dengue and yellow fever-challenges for the development and use of vaccines.","volume":"357","author":"TP Monath","year":"2007","journal-title":"N Engl J Med"},{"key":"ref11","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1016\/j.vaccine.2008.09.009","article-title":"Adverse event reports following yellow fever vaccination.","volume":"26","author":"NP Lindsey","year":"2008","journal-title":"Vaccine"},{"key":"ref12","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jcv.2006.02.005","article-title":"Yellow fever vaccine-associated viscerotropic disease and death in Spain.","volume":"36","author":"A Doblas","year":"2006","journal-title":"J Clin Virol"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/S0140-6736(01)05327-2","article-title":"Fever and multisystem organ failure associated with 17D-204 yellow fever vaccination: a report of four cases.","volume":"358","author":"M Martin","year":"2001","journal-title":"Lancet"},{"key":"ref14","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/S0140-6736(01)05326-0","article-title":"Serious adverse events associated with yellow fever 17DD vaccine in Brazil: a report of two cases.","volume":"358","author":"PF Vasconcelos","year":"2001","journal-title":"Lancet"},{"key":"ref15","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0140-6736(01)05341-7","article-title":"Hepatitis and death following vaccination with 17D-204 yellow fever vaccine.","volume":"358","author":"RC Chan","year":"2001","journal-title":"Lancet"},{"key":"ref16","first-page":"131","article-title":"Fatal myeloencephalitis following yellow fever vaccination in a case with HIV infection.","volume":"85","author":"K Kengsakul","year":"2002","journal-title":"J Med Assoc Thai"},{"key":"ref17","doi-asserted-by":"crossref","first-page":"8480","DOI":"10.1016\/j.vaccine.2007.08.061","article-title":"Fatal multiorgan failure due to yellow fever vaccine-associated viscerotropic disease.","volume":"25","author":"JL Belsher","year":"2007","journal-title":"Vaccine"},{"key":"ref18","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1097\/01.SMJ.0000157537.11806.DC","article-title":"Rare case of fatal yellow fever vaccine-associated viscerotropic disease.","volume":"98","author":"G Gerasimon","year":"2005","journal-title":"South Med J"},{"key":"ref19","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1093\/infdis\/161.6.1134","article-title":"Immunogenicity of a purified fragment of 17D yellow fever envelope protein.","volume":"161","author":"MW Brandriss","year":"1990","journal-title":"J Infect Dis"},{"key":"ref20","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0042-6822(92)90317-I","article-title":"Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis.","volume":"187","author":"S Pincus","year":"1992","journal-title":"Virology"},{"issue":"Pt 8","key":"ref21","doi-asserted-by":"crossref","first-page":"1697","DOI":"10.1099\/0022-1317-71-8-1697","article-title":"Protection of mice against yellow fever virus encephalitis by immunization with a vaccinia virus recombinant encoding the yellow fever virus non-structural proteins, NS1, NS2a and NS2b.","volume":"71","author":"JR Putnak","year":"1990","journal-title":"J Gen Virol"},{"issue":"Pt 2","key":"ref22","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1099\/0022-1317-67-2-229","article-title":"Lethal 17D yellow fever encephalitis in mice. I. Passive protection by monoclonal antibodies to the envelope proteins of 17D yellow fever and dengue 2 viruses.","volume":"67","author":"MW Brandriss","year":"1986","journal-title":"J Gen Virol"},{"key":"ref23","doi-asserted-by":"crossref","first-page":"3827","DOI":"10.1016\/j.vaccine.2010.03.023","article-title":"Inactivated yellow fever 17D vaccine: development and nonclinical safety, immunogenicity and protective activity.","volume":"28","author":"TP Monath","year":"2010","journal-title":"Vaccine"},{"key":"ref24","doi-asserted-by":"crossref","first-page":"2107","DOI":"10.1128\/JVI.75.5.2107-2118.2001","article-title":"Yellow fever virus encephalitis: properties of the brain-associated T-cell response during virus clearance in normal and gamma interferon-deficient mice and requirement for CD4+ lymphocytes.","volume":"75","author":"T Liu","year":"2001","journal-title":"J Virol"},{"key":"ref25","doi-asserted-by":"crossref","first-page":"7919","DOI":"10.4049\/jimmunol.0803903","article-title":"The yellow fever virus vaccine induces a broad and polyfunctional human memory CD8+ T cell response.","volume":"183","author":"RS Akondy","year":"2009","journal-title":"J Immunol"},{"key":"ref26","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1016\/j.immuni.2008.02.020","article-title":"Human effector and memory CD8+ T cell responses to smallpox and yellow fever vaccines.","volume":"28","author":"JD Miller","year":"2008","journal-title":"Immunity"},{"key":"ref27","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1006\/viro.2002.1432","article-title":"Yellow fever virus 17D envelope and NS3 proteins are major targets of the antiviral T cell response in mice.","volume":"296","author":"RG van der Most","year":"2002","journal-title":"Virology"},{"key":"ref28","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1006\/viro.2001.1255","article-title":"Human cytotoxic T lymphocyte responses to live attenuated 17D yellow fever vaccine: identification of HLA-B35-restricted CTL epitopes on nonstructural proteins NS1, NS2b, NS3, and the structural protein E.","volume":"293","author":"MD Co","year":"2002","journal-title":"Virology"},{"key":"ref29","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.virol.2008.04.043","article-title":"Comprehensive analysis of T cell epitope discovery strategies using 17DD yellow fever virus structural proteins and BALB\/c (H2d) mice model.","volume":"378","author":"M Maciel Jr","year":"2008","journal-title":"Virology"},{"key":"ref30","doi-asserted-by":"crossref","DOI":"10.1007\/BF01641272","article-title":"Abstammung, Eigenschaften und Verwendung des attenuierten Vaccinia-Stammes MVA.","author":"A Mayr","year":"1975"},{"key":"ref31","doi-asserted-by":"crossref","first-page":"e2921","DOI":"10.1371\/journal.pone.0002921","article-title":"Safety and immunogenicity of the candidate tuberculosis vaccine MVA85A in West Africa.","volume":"3","author":"RH Brookes","year":"2008","journal-title":"PLoS One"},{"key":"ref32","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.vaccine.2005.08.041","article-title":"Phase I clinical trial safety of DNA- and modified virus Ankara-vectored human immunodeficiency virus type 1 (HIV-1) vaccines administered alone and in a prime-boost regime to healthy HIV-1-uninfected volunteers.","volume":"24","author":"I Cebere","year":"2006","journal-title":"Vaccine"},{"key":"ref33","doi-asserted-by":"crossref","first-page":"e707","DOI":"10.1371\/journal.pone.0000707","article-title":"Extended follow-up following a phase 2b randomized trial of the candidate malaria vaccines FP9 ME-TRAP and MVA ME-TRAP among children in Kenya.","volume":"2","author":"P Bejon","year":"2007","journal-title":"PLoS One"},{"key":"ref34","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1186\/1479-5876-7-2","article-title":"Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma.","volume":"7","author":"HL Kaufman","year":"2009","journal-title":"J Transl Med"},{"key":"ref35","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.copbio.2004.09.001","article-title":"Modified vaccinia virus Ankara as antigen delivery system: how can we best use its potential?","volume":"15","author":"I Drexler","year":"2004","journal-title":"Curr Opin Biotechnol"},{"key":"ref36","first-page":"2386","article-title":"[MVA vaccination against smallpox: clinical tests with an attenuated live vaccinia virus strain (MVA) (author's transl)].","volume":"99","author":"H Stickl","year":"1974","journal-title":"Dtsch Med Wochenschr"},{"key":"ref37","first-page":"375","article-title":"[The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].","volume":"167","author":"A Mayr","year":"1978","journal-title":"Zentralbl Bakteriol B"},{"key":"ref38","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1007\/s00262-007-0428-7","article-title":"Vaccination of colorectal cancer patients with TroVax given alongside chemotherapy (5-fluorouracil, leukovorin and irinotecan) is safe and induces potent immune responses.","volume":"57","author":"R Harrop","year":"2008","journal-title":"Cancer Immunol Immunother"},{"key":"ref39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/viro.1998.9397","article-title":"Marker rescue of the host range restriction defects of modified vaccinia virus Ankara.","volume":"251","author":"LS Wyatt","year":"1998","journal-title":"Virology"},{"issue":"Pt 2","key":"ref40","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1099\/0022-1317-79-2-347","article-title":"Highly attenuated modified vaccinia virus Ankara replicates in baby hamster kidney cells, a potential host for virus propagation, but not in various human transformed and primary cells.","volume":"79","author":"I Drexler","year":"1998","journal-title":"J Gen Virol"},{"key":"ref41","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1006\/viro.1997.8845","article-title":"Host range and cytopathogenicity of the highly attenuated MVA strain of vaccinia virus: propagation and generation of recombinant viruses in a nonhuman mammalian cell line.","volume":"238","author":"MW Carroll","year":"1997","journal-title":"Virology"},{"key":"ref42","doi-asserted-by":"crossref","first-page":"5192","DOI":"10.1128\/JVI.02081-08","article-title":"Nonreplicating vaccinia virus vectors expressing the H5 influenza virus hemagglutinin produced in modified Vero cells induce robust protection.","volume":"83","author":"J Mayrhofer","year":"2009","journal-title":"J Virol"},{"key":"ref43","doi-asserted-by":"crossref","first-page":"4997","DOI":"10.1128\/JVI.71.7.4997-5002.1997","article-title":"Construction of a vaccinia virus deficient in the essential DNA repair enzyme uracil DNA glycosylase by a complementing cell line.","volume":"71","author":"GW Holzer","year":"1997","journal-title":"J Virol"},{"key":"ref44","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1128\/JVI.76.15.7713-7723.2002","article-title":"Immunogenicity and safety of defective vaccinia virus lister: comparison with modified vaccinia virus Ankara.","volume":"76","author":"BT Ober","year":"2002","journal-title":"J Virol"},{"key":"ref45","doi-asserted-by":"crossref","first-page":"1137-6","DOI":"10.2144\/00286st04","article-title":"Transient host range selection for genetic engineering of modified vaccinia virus Ankara.","volume":"28","author":"C Staib","year":"2000","journal-title":"Biotechniques"},{"key":"ref46","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/viro.1998.9307","article-title":"Dominant host range selection of vaccinia recombinants by rescue of an essential gene.","volume":"249","author":"GW Holzer","year":"1998","journal-title":"Virology"},{"key":"ref47","doi-asserted-by":"crossref","first-page":"726","DOI":"10.1126\/science.4023707","article-title":"Nucleotide sequence of yellow fever virus: implications for flavivirus gene expression and evolution.","volume":"229","author":"CM Rice","year":"1985","journal-title":"Science"},{"key":"ref48","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1007\/s007050050303","article-title":"Transient marker stabilisation: a general procedure to construct marker-free recombinant vaccinia virus.","volume":"143","author":"F Scheiflinger","year":"1998","journal-title":"Arch Virol"},{"key":"ref49","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1016\/j.vaccine.2007.11.036","article-title":"Correlation of immunogenicities and in vitro expression levels of recombinant modified vaccinia virus Ankara HIV vaccines.","volume":"26","author":"LS Wyatt","year":"2008","journal-title":"Vaccine"},{"key":"ref50","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1016\/S0264-410X(96)00072-2","article-title":"Development of a replication-deficient recombinant vaccinia virus vaccine effective against parainfluenza virus 3 infection in an animal model.","volume":"14","author":"LS Wyatt","year":"1996","journal-title":"Vaccine"},{"key":"ref51","first-page":"375","article-title":"The Togaviridae and Flaviviridae.","author":"TP Monath","year":"1986"},{"key":"ref52","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.jim.2003.10.017","article-title":"The VITAL assay: a versatile fluorometric technique for assessing CTL- and NKT-mediated cytotoxicity against multiple targets in vitro and in vivo.","volume":"285","author":"IF Hermans","year":"2004","journal-title":"J Immunol Methods"},{"key":"ref53","doi-asserted-by":"crossref","first-page":"923","DOI":"10.1128\/JVI.74.2.923-933.2000","article-title":"Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine.","volume":"74","author":"JC Ramirez","year":"2000","journal-title":"J Virol"},{"key":"ref54","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0264-410X(98)00156-X","article-title":"Protection against lethal Japanese encephalitis virus infection of mice by immunization with the highly attenuated MVA strain of vaccinia virus expressing JEV prM and E genes.","volume":"17","author":"JH Nam","year":"1999","journal-title":"Vaccine"},{"key":"ref55","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1517\/14712590802567298","article-title":"Development of modified vaccinia Ankara-5T4 as specific immunotherapy for advanced human cancer.","volume":"8","author":"SS Tykodi","year":"2008","journal-title":"Expert Opin Biol Ther"},{"key":"ref56","doi-asserted-by":"crossref","first-page":"4132","DOI":"10.1016\/j.vaccine.2011.03.089","article-title":"Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection.","volume":"29","author":"GW Holzer","year":"2011","journal-title":"Vaccine"},{"key":"ref57","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1128\/JVI.77.2.813-820.2003","article-title":"Role of the transmembrane domains of prM and E proteins in the formation of yellow fever virus envelope.","volume":"77","author":"BA Op De","year":"2003","journal-title":"J Virol"},{"key":"ref58","doi-asserted-by":"crossref","first-page":"6756","DOI":"10.4049\/jimmunol.163.12.6756","article-title":"A DNA immunization model study with constructs expressing the tick-borne encephalitis virus envelope protein E in different physical forms.","volume":"163","author":"JH Aberle","year":"1999","journal-title":"J Immunol"},{"key":"ref59","doi-asserted-by":"crossref","first-page":"1102","DOI":"10.1086\/501459","article-title":"Safety profile of the viral vectors of attenuated fowlpox strain FP9 and modified vaccinia virus Ankara recombinant for either of 2 preerythrocytic malaria antigens, ME-TRAP or the circumsporozoite protein, in children and adults in Kenya.","volume":"42","author":"P Bejon","year":"2006","journal-title":"Clin Infect Dis"},{"key":"ref60","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1089\/aid.2006.0226","article-title":"Evaluation of modified vaccinia virus Ankara as an alternative vaccine against smallpox in chronically HIV type 1-infected individuals undergoing HAART.","volume":"23","author":"A Cosma","year":"2007","journal-title":"AIDS Res Hum Retroviruses"},{"key":"ref61","doi-asserted-by":"crossref","first-page":"3416","DOI":"10.1158\/1078-0432.CCR-05-2732","article-title":"Vaccination of colorectal cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) induces immune responses which correlate with disease control: a phase I\/II trial.","volume":"12","author":"R Harrop","year":"2006","journal-title":"Clin Cancer Res"},{"key":"ref62","doi-asserted-by":"crossref","first-page":"7651","DOI":"10.1128\/JVI.74.16.7651-7655.2000","article-title":"Attenuated modified vaccinia virus Ankara can be used as an immunizing agent under conditions of preexisting immunity to the vector.","volume":"74","author":"JC Ramirez","year":"2000","journal-title":"J Virol"},{"key":"ref63","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1016\/0140-6736(91)91636-9","article-title":"Safety of and immunological response to a recombinant vaccinia virus vaccine expressing HIV envelope glycoprotein.","volume":"337","author":"EL Cooney","year":"1991","journal-title":"Lancet"},{"key":"ref64","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1128\/JVI.62.5.1530-1534.1988","article-title":"Immunization with a vaccinia virus recombinant expressing herpes simplex virus type 1 glycoprotein D: long-term protection and effect of revaccination.","volume":"62","author":"JF Rooney","year":"1988","journal-title":"J Virol"},{"key":"ref65","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1126\/science.2992092","article-title":"Recombinant vaccinia virus: immunization against multiple pathogens.","volume":"229","author":"ME Perkus","year":"1985","journal-title":"Science"},{"key":"ref66","doi-asserted-by":"crossref","first-page":"B281","DOI":"10.1093\/gerona\/53A.4.B281","article-title":"Immunogenicity and efficacy of a DNA vaccine in aged mice.","volume":"53","author":"DM Klinman","year":"1998","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"ref67","doi-asserted-by":"crossref","first-page":"4456","DOI":"10.1128\/IAI.64.11.4456-4462.1996","article-title":"Cellular basis of decreased immune responses to pneumococcal vaccines in aged mice.","volume":"64","author":"M Garg","year":"1996","journal-title":"Infect Immun"},{"key":"ref68","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/infdis\/168.4.873","article-title":"Heterotypic immune mice lose protection against influenza virus infection with senescence.","volume":"168","author":"BS Bender","year":"1993","journal-title":"J Infect Dis"},{"issue":"Pt 4","key":"ref69","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1099\/0022-1317-67-4-631","article-title":"Comparison of neurovirulence of different strains of yellow fever virus in mice.","volume":"67","author":"AD Barrett","year":"1986","journal-title":"J Gen Virol"},{"key":"ref70","doi-asserted-by":"crossref","first-page":"1431","DOI":"10.1086\/320199","article-title":"Experimental yellow fever virus infection in the Golden Hamster (Mesocricetus auratus). I. Virologic, biochemical, and immunologic studies.","volume":"183","author":"RB Tesh","year":"2001","journal-title":"J Infect Dis"},{"key":"ref71","doi-asserted-by":"crossref","first-page":"e1000614","DOI":"10.1371\/journal.ppat.1000614","article-title":"A mouse model for studying viscerotropic disease caused by yellow fever virus infection.","volume":"5","author":"KC Meier","year":"2009","journal-title":"PLoS Pathog"}],"container-title":["PLoS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0024505","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,11]],"date-time":"2024-04-11T06:57:23Z","timestamp":1712818643000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0024505"}},"subtitle":[],"editor":[{"given":"Samithamby","family":"Jeyaseelan","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2011,9,9]]},"references-count":71,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2011,9,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0024505","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2011,9,9]]}}}